Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: A quantitative synthesis of double-blind studies

International Clinical Psychopharmacology

Volumn 24, Issue 1, 2009, Pages 19-25

  Papakostas, George I ^a,b   Cooper Kazaz, Rena ^d   Appelhof, Bente C ^b   Posternak, Michael A ^a   Johnson, Daniel P ^a   Klibanski, Anne ^c   Lerer, Bernard ^d   Fava, Maurizio ^a  

^a Depression Clin and Res Program   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Analysis; Augmentation; Depressive; Disorder; Major; Meta; Rapidity; Remission; Selective serotonin reuptake inhibitor; Thyroid

Indexed keywords

AMFEBUTAMONE; D 1 DEIODINASE; IODIDE PEROXIDASE; LIOTHYRONINE; MIRTAZAPINE; MONOAMINE OXIDASE A INHIBITOR; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ARTICLE; ATYPICAL DEPRESSION; CLINICAL TRIAL; DEIODINATION; DIO1 GENE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENE; GENETIC POLYMORPHISM; HUMAN; MAJOR DEPRESSION; META ANALYSIS; PATIENT SELECTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QUANTITATIVE ANALYSIS; RANDOMIZATION; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; TRIIODOTHYRONINE;

EID: 58349093751     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328314dfaf     Document Type: Article

References (26)

1. Altshuler LL, Bauer M, Frye MA, Gitlin MJ, Mintz J, Szuba MP, et al. (2001). Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry 158:1617-1622.
2. Appelhof BC, Brouwer JP, van Dyck R, Fliers E, Hoogendijk WJ, Huyser J, et al. (2004). Triiodothyronine addition to paroxetine in the treatment of major depressive disorder. J Clin Endocrinol Metab 89:6271-6276.
3. Aronson R, Offman HJ, Joffe RT, Naylor CD (1996). Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 53:842-848.
4. Cooper-Kazaz R, Lerer B (2008). Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. Int J Neuropsychopharmacol 11: 685-699.
5. Cooper-Kazaz R, Apter JT, Cohen R, Karagichev L, Muhammed-Moussa S, Grupper D, et al. (2007). Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 64:679-688.
6. Cooper-Kazaz R, van der Deure WN, Visser TJ, Alkelai A, Glaser B, Peeters RP, Lerer B (submitted). A functional polymorphism in the D-1 deiodinase gene is associated with enhanced potentiation by triiodothyronine (T3) of the antidepressant effect of sertraline.
7. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials 7:177-188.
8. Fava M, Rush AJ (2006). Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom 75: 139-153.
9. Fava M, Rush AJ, Wisniewski SR, Nierenberg AA, Alpert JE, McGrath PJ, et al. (2006). A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR'D report. Am J Psychiatry 163:1161-1172.
10. Feighner JP, King LJ, Schuckit MA, Croughan J, Briscoe W (1972). Hormonal potentiation of imipramine and ECT in primary depression. Am J Psychiatry 128:1230-1238.
11. Garlow SJ, Dunlop B, Ninan PT, Nemeroff CB (submitted). Addition of triiodothyronine (T3) to sertraline does not impact treatment response in patients with major depressive disorder.
12. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
13. losifescu DV, Nierenberg AA, Mischoulon D, Perlis RH, Papakostas Gl, Ryan JL, et al. (2005). An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. J Clin Psychiatry 66:1038-1042.
14. Laird NM, Mosteller F (1990). Some statistical methods for combining experimental results. Int J Technol Assess Health Care 6:5-30.
15. *D report. Am J Psychiatry 163:1531-1541.
16. Montgomery SA, Asberg A (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
17. Mosteller F, Colditz GA (1996). Understanding research synthesis (metaanalysis). Annu Rev Public Health 17:1-23.
18. Papakostas Gl, Fava M (2005). Monoamine-based pharmacotherapy. In: Licinio J, editor. Biology of depression: from novel insights to therapeutic strategies. 1st ed. Weinheim: Wiley-VCH Verlag. pp. 87-140.
19. Posternak M, Novak S, Stern R, Hennessey J, Joffe R, Prange A, Zimmerman M (2008). A pilot effectiveness study: placebo-controlled trial of adjunctive L-triiodothyronine (T3) used to accelerate and potentiate the antidepressant response. Int J Neuropsychopharmacol 11:15-25.
20. Prange AJ Jr, Wilson IC, Rabon AM, Upton MA (1969). Enhancement of imipramine antidepressant activity by thyroid hormone. Am J Psychiatry 126: 457-469.
21. Quitkin FM, Petkova E, McGrath PJ, Taylor B, Beasley C, Stewart J, et al. (2003). When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry 160:734-740.
22. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, et al. (2006). Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354:1231-1242.
23. Soares CN, Papakostas Gl (2007). Neuroendocrine-based treatments for depression, Dir Psychiatty 27:83-98.
24. *D: implications for clinical practice. Am J Psychiatry 163:28-40.
25. Wheatley D (1972). Potentiation of amitriptyline by thyroid hormone. Arch Gen Psychiatry 26:229-233.
26. Wilson IC, Prange AJ Jr, McClane TK, Rabon AM, Lipton MA (1970). Thyroidhormone enhancement of imipramine in nonretarded depressions. New Engl J Med 282:1063-1067.